title: [Schizophrenia, diabetes and new neuroleptics].
abstract: Diabetes mellitus occurs more frequently in schizophrenic patients. The use of a novel antipsychotic drug seems to be concomitant to a further increase in imbalance of blood glucose homeostasis. Such cases have already been reported in the literature indicating that diabetes mellitus might be a real side effect of this novel class of neuroleptics. In conclusion, it seems that schizophrenic patients under such treatment would greatly benefit from a closer clinical and biological follow up regarding glucose metabolism. Further randomised studies would be needed.
authors.affiliation: Secteur Psychiatrique Ouest, Hôpital Psychiatrique de Prangins.
authors.forename: G
authors.initials: G
authors.lastname: Ambresin
authors.forename: Ch
authors.initials: Ch
authors.lastname: Bryois
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced; D006801:Humans; D018570:Risk Assessment; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents